Erythroderma (exfoliative dermatitis). Part 1: underlying causes, clinical presentation and pathogenesis
Tso, Simon Satchwell, Francesca Moiz, Haseeb Hari, Tushar Dhariwal, S. Barlow, Richard Forbat, E. Randeva, Harpal Tan, Yu Ting Ilchyshyn, A.
Tso, Simon
Satchwell, Francesca
Moiz, Haseeb
Hari, Tushar
Dhariwal, S.
Barlow, Richard
Forbat, E.
Randeva, Harpal
Tan, Yu Ting
Ilchyshyn, A.
Citations
Altmetric:
Affiliation
South Warwickshire University NHS Foundation Trust; University of Warwick; University of Buckingham; University Hospitals Coventry and Warwickshire NHS Trust; Worcestershire Acute Hospitals NHS Trust; Westmead Hospital, Sydney, Australia; Tan Tock Seng Hospital, Singapore
Other Contributors
Publication date
2021-08
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Erythroderma (exfoliative dermatitis), first described by Von Hebra in 1868, manifests as a cutaneous inflammatory state, with associated skin barrier and metabolic dysfunctions. The annual incidence of erythroderma is estimated to be 1-2 per 100 000 population in Europe with a male preponderance. Erythroderma may present at birth, or may develop acutely or insidiously (due to progression of an underlying primary pathology, including malignancy). Although there is a broad range of diseases that associate with erythroderma, the vast majority of cases result from pre-existing and chronic dermatoses. In the first part of this two-part concise review, we explore the underlying causes, clinical presentation, pathogenesis and investigation of erythroderma, and suggest potential treatment targets for erythroderma with unknown causes.
Citation
Tso S, Satchwell F, Moiz H, Hari T, Dhariwal S, Barlow R, Forbat E, Randeva H, Tan YT, Ilchyshyn A, Kwok MM, Barber TM, Thind C, Tso ACY. Erythroderma (exfoliative dermatitis). Part 1: underlying causes, clinical presentation and pathogenesis. Clin Exp Dermatol. 2021 Aug;46(6):1001-1010. doi: 10.1111/ced.14625. Epub 2021 May 1.
Type
Article